^
Association details:
| Biomarker: | TMB-H |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | Tyvyt (sintilimab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
IBI308 in Subjects With Advanced/Metastatic Solid Malignancies
Excerpt:
...Cohort 1: Advanced/metastatic cancers with high TMB expression i....
Trial ID:
Source:
Title:
784 Biomarkers of perioperative immunotherapy in combination with concurrent chemoradiotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma
Published date:
11/04/2023
Excerpt:
34 patients with locally advanced G/GEJ cancer received anti-PD-1 therapy (Sintilimab)...Our results met the pre-specified primary endpoint, with a pCR rate of 38.2% and median DFS of 17.0 months. Tumor mutation burden (TMB) analyzed by NGS was significantly higher in the pCR group than those not achieving pCR (non-pCR)...Biomarker analysis by mIF showed patients with positive PD-L1 expression showed a numerically higher pCR rate...positive PD-L1 expression, higher T cell infiltration and TMB could be predictive biomarkers of perioperative anti-PD-1 therapy in combination with cCRT for locally advanced G/GEJ.
DOI:
10.1136/jitc-2023-SITC2023.0784
Trial ID:
Source:
Title:
Matched therapies for advanced gastric cancer based on genotype: A real-world study in China.
Published date:
05/19/2021
Excerpt:
...6 (20%) dMMR/MSI-H/TMB-H (received sintilimab, pembrolizumab, tislelizumab or nivolumab, combined with antivascular or not, cohort C)...In cohort C, ORR was 17% (1/6), DCR was 67% (4/6), mPFS and mOS was 1.9 months and 6.8 months, respectively.
DOI:
http://admin.larvolinsight.com/Entities/BiomarkerAssociationManager/Detail.aspx?BiomarkerAssociationId=0c5d2211-7994-4457-94a0-c89cde21def0
